Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: Mar 31, 2025
– FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track –
– Enrolling approximately one patient per week across the RESET™ clinical development program since ACR Convergence presentation in November 2024 with 33 patients enrolled across 56 active clinical trial sites in the U.S. & Europe as of March 14, 2025 –
Read more at globenewswire.com1.57
-0.13 (-7.65%)
Find more stocks in the Stock Screener
CABA Latest News and Analysis
17 days ago - ChartmillLet's have a look at the top gainers and losers one hour before the close of the markets of today's session.Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
17 days ago - ChartmillTop movers analysis in the middle of the day on 2025-06-11: top gainers and losers in today's session.Curious about what's happening in today's session? Check out the latest stock movements and price changes.
17 days ago - ChartmillWhich stocks are gapping on Wednesday?Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps.
